Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline


GT Biopharma, Inc. a targeted immunotherapies company with close to market treatments for Central Nervous System diseases.


Latest News

GT Biopharma Announces Dosing First Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
Feb 26, 2020 • 8:00 EST | Read More

GT Biopharma Provides Update Concerning Trike(TM) Drug Development Programs and Other Strategic Initiatives
Jan 21, 2020 • 8:45 EST | Read More


GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range